VR Logo

POINT Biopharma Global Inc. (PNT) download report


Healthcare | Biotechnology & Pharma Research

POINT Biopharma Global Inc. (PNT) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer.

IPO Date: 08-Jul-2020

Exec. Chairman: Mr. Allan Charles Silber

CEO & Director: Dr. Joe A. McCann Ph.D.

Listing: NASDAQ: PNT

Country: United States

Headquarters: Indianapolis, IN

Website: https://www.pointbiopharma.com

Key Facts

Market cap: $656.10 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-60.88 Mln

Cash: $227.39 Mln

Total Debt: $0.00 Mln

Insider's Holding: 17.90%

Liquidity: Low

52 Week range: $4.25 - 11.72

Shares outstanding: 90,124,304

Stock Performance

Time Period POINT Biopharma Global (PNT) S&P BSE Sensex S&P Small-Cap 600
YTD30.00-9.18-18.78
1 month-10.34-4.78-8.00
3 months-8.66-9.66-13.65
1 Year-29.140.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year POINT Biopharma Global (PNT) S&P Small-Cap 600 S&P BSE Sensex
2021-59.7725.2721.99